Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of “Moderate Buy” by Brokerages
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AMH Equity Ltd Buys New Position in Orchestra BioMed Holdings, Inc. $OBIO
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Orchestra BioMed to Host Business Update Call on November 12, 2025
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
Orchestra BioMed Announces Pricing of $40 Million Public Offering
Orchestra BioMed Announces Proposed Public Offering
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025
Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones
Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
Orchestra BioMed to Present at Upcoming Investor Conferences
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board